At 2 mg per week, the 10 mg vial provides five full weeks of supply
These essential fats help maintain healthy cholesterol and triglyceride levels, and support overall cardiovascular function
After two weeks, all except amiloride demonstrated a significant reduction in ICP ranging from 10.3% to 14.5%, with no significant superiority of one drug over another
To the best of our knowledge, this meta-analysis is the first to evaluate the effects and safety of SGLT2i and GLP-1RAs as first-line therapy for T2DM with low cardiovascular risk
In prior studies, it was found that these two classes of drugs showed heart and kidney benefits besides controlling blood sugar.[3] The researchers analyzed data from six previous trials of GLP-1 (including a total of 51,762 subjects) and four trials of SGLT2 inhibitors (including 33,457 subjects)